{
    "clinical_study": {
        "@rank": "124536", 
        "arm_group": [
            {
                "arm_group_label": "Everolimus", 
                "arm_group_type": "Experimental", 
                "description": "everolimus dosing to tough level 6-10 ng/ml"
            }, 
            {
                "arm_group_label": "Tacrolimus", 
                "arm_group_type": "Experimental", 
                "description": "Tacrolimus dosing to target tough level 5-10 ng/ml"
            }
        ], 
        "brief_summary": {
            "textblock": "The calcineurin inhibitor drugs including cyclosporin and tacrolimus are well-known as\n      nephrotoxicity. However, these drugs are essential for kidney transplant especially in high\n      immunological risks. To date, however, there is an alternative regimen by using of\n      everolimus-based which showing less toxicity than tacrolimus-based regimen by its\n      mechanisms. Of note, this study aims to evaluate the toxicity by using microRNA profiles\n      detection between everolimus-based and tacrolimus-based immunosuppressive regimen in kidney\n      transplantation."
        }, 
        "brief_title": "MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "microRNA Profiles", 
        "detailed_description": {
            "textblock": "The author aims to evaluate the effects of two regimens (everolimus-based versus\n      tacrolimus-based) in kidney transplantation recipients. Both of regimens are prescribed only\n      in recipents who have low immunologicla risks. After informed consent, all eligible\n      recipients will be collected blood and urine sample for microRNA profile testing during\n      study periods."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have given informed consent to participate in the study\n\n          -  Actual eGFR > 20-25 ml/min/1.73 m2\n\n        Exclusion Criteria:\n\n          -  Multi-organ transplantation\n\n          -  Pregnancy\n\n          -  ABO incompatible blood group\n\n          -  Second, third, fouth kidney transplantation\n\n          -  HIV positive, active or carrier in any infections"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091973", 
            "org_study_id": "WWC-004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Everolimus", 
                "description": "Everolimus dosing to target tough level 6-10 mg/ml", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tacrolimus", 
                "description": "Tacrolimus dosing to target tough level 5-10 ng/ml", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "everolimus", 
            "tacrolimus", 
            "kidney transplantation", 
            "microRNA"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "contact": {
                "email": "wiwatmd@hotmail.com", 
                "last_name": "Wiwat Chancharoenthana, MD, MSc", 
                "phone": "6622564251", 
                "phone_ext": "106"
            }, 
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10330"
                }, 
                "name": "Chulalongkorn University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Maintenance Immunosuppressive Regimens in Kidney Transplantation", 
        "overall_contact": {
            "email": "wiwatmd@hotmail.com", 
            "last_name": "Wiwat Chancharoenthana, MD, MSc.", 
            "phone": "6622564251", 
            "phone_ext": "101"
        }, 
        "overall_official": [
            {
                "affiliation": "Chulalongkorn University", 
                "last_name": "Wiwat Chancharoenthana, MD, Msc.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chulalongkorn University", 
                "last_name": "Wiwat Chancharoenthana, MD, MSc.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "microRNA profiles including rejection and nephrotoxicity markers", 
            "measure": "microRNA profiles", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091973"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chulalongkorn University", 
            "investigator_full_name": "Wiwat Chancharoenthana", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Pathology studies including rejection, interstitial fibrosis and tubular atrophy", 
            "measure": "Allograft tissue pathology", 
            "safety_issue": "No", 
            "time_frame": "At year 2 and 5"
        }, 
        "source": "Chulalongkorn University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chulalongkorn University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}